Risk-based Methodology for Validation of Pharmaceutical Batch Processes

Area of Science:

• Pharmaceutical Science
• Process Validation
• Statistical Quality Control

Background:

• The 2011 U.S. Food and Drug Administration (FDA) process validation guidance shifted from a fixed number of batches to a risk-based statistical approach.
• The previous industry standard of three consecutive validation batches is no longer considered sufficient to demonstrate process control.
• A need exists for a statistical methodology to determine adequate sampling and runs for process performance qualification (PPQ).

Purpose of the Study:

• To propose a statistical methodology for determining the number of validation runs and samples for pharmaceutical batch processes.
• To align process validation practices with the FDA's 2011 guidance emphasizing statistical confidence.
• To provide a framework for demonstrating a process operates in a validated state using risk assessment and statistical tools.

Main Methods:

• Utilized a combination of risk assessment (Process Failure Mode, Effects, and Criticality Analysis - PFMECA) and statistical methods.
• Employed capability statistics to determine when Stage 2 (PPQ) milestones are met.
• Incorporated control charting (Individuals, Moving Range, Range/Sigma) to demonstrate statistical control during commercial production.

Main Results:

• The proposed methodology allows for the determination of statistically sound monitoring and testing schemes for PPQ.
• PFMECA output informs the selection of statistical confidence and coverage levels for capability calculations.
• Successful achievement of Stage 2 milestones enables commercial batch release and reduced monitoring.

Conclusions:

• A risk-based methodology combining PFMECA, capability statistics, and control charting provides a robust approach to pharmaceutical process validation.
• This approach ensures statistical confidence within and between batches, satisfying FDA guidance requirements.
• The methodology facilitates the transition from PPQ to commercial production with demonstrated process control.